Want to see STLN full AI Analyst Report?
STLN Stock Chart & Stats
$6.56
$0.21(4.22%)
At close: 4:00 PM EDT
$6.56
$0.21(4.22%)
Day’s Range― - ―
52-Week Range$2.32 - $7.13
Previous Close$5.21
VolumeN/A
Average Volume (3M)1.41M
Market Cap
$695.88M
Enterprise Value$622.84
Total Cash (Recent Filing)$41.09M
Total Debt (Recent Filing)$104.48M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Nov 11, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding99,982,930
10 Day Avg. Volume1,184,291
30 Day Avg. Volume1,412,267
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-34.09
Price to Sales (P/S)1.07
P/FCF Ratio-19.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.25Price Target Upside41.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$663.59M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained revenue growth indicates expanding patient, payer and service volumes. Higher scale can improve operating leverage and support the company’s transition toward more predictable, recurring value-based oncology revenue.
Capitated Contract ExpansionAdding capitated lives broadens payer relationships and increases recurring revenue potential. Larger attributed populations also give TOI more opportunity to apply care pathways, manage costs and build a scalable value-based oncology platform.
Improving Cash Flow And Operating EfficiencyThe sharp improvement in operating cash flow and lower selling, general and administrative costs suggest better conversion of growth into liquidity. If sustained, these gains can reduce funding needs and improve the economics of expansion.
Bears Say
Negative Equity And Elevated LeverageNegative equity reflects accumulated losses and leaves limited balance-sheet capacity to absorb setbacks. Significant debt increases refinancing dependence and may constrain investment, contracting flexibility and resilience if growth or profitability falters.
Profitability And Free Cash Flow Not Yet EstablishedDespite recent adjusted EBITDA and cash-flow improvements, reported earnings power remains unproven and TTM free cash flow is negative. Continued losses could require external funding and make future growth dependent on execution remaining strong.
Medical Loss Ratio And Patient Services PressureHigh and volatile medical loss ratios can compress margins as new capitated members are onboarded. Lower Patient Services profit signals that staffing and care-management costs may run ahead of revenue until contracts mature and pathways improve.
Starling Oncology Institute News
STLN FAQ
What was Starling Oncology Institute’s price range in the past 12 months?
Starling Oncology Institute lowest stock price was $2.32 and its highest was $7.13 in the past 12 months.
What is Starling Oncology Institute’s market cap?
Starling Oncology Institute’s market cap is $695.88M.
When is Starling Oncology Institute’s upcoming earnings report date?
Starling Oncology Institute’s upcoming earnings report date is Nov 11, 2026 which is in 52 days.
How were Starling Oncology Institute’s earnings last quarter?
Starling Oncology Institute released its earnings results on Aug 06, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.064 by -$0.016.
Is Starling Oncology Institute overvalued?
According to Wall Street analysts Starling Oncology Institute’s price is currently Undervalued.
Does Starling Oncology Institute pay dividends?
Starling Oncology Institute does not currently pay dividends.
What is Starling Oncology Institute’s EPS estimate?
Starling Oncology Institute’s EPS estimate is -0.05.
How many shares outstanding does Starling Oncology Institute have?
Starling Oncology Institute has 99,982,930 shares outstanding.
What happened to Starling Oncology Institute’s price movement after its last earnings report?
Starling Oncology Institute reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.064. Following the earnings report the stock price went up 28.457%.
Which hedge fund is a major shareholder of Starling Oncology Institute?
Currently, no hedge funds are holding shares in STLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Starling Oncology Institute Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.25 (41.01% Upside)
$9.25 (41.01% Upside)
Blogger Sentiment
Bullish
STLN Sentiment 100%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Decreased
By 12.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
114.81%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.54%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Starling Oncology Institute
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
STLN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong revenue growth (34.6% YoY), robust Specialty Pharmacy performance (57.6% revenue growth; 85.1% gross profit growth), improved margins and the company's second profitable quarter as a public company with positive adjusted EBITDA. Cash flow turned positive, free cash flow improved materially, and a refinancing strengthened the balance sheet without dilution. Management also announced meaningful capitated contract wins that add substantial lives and annualized capitation revenue, and they launched a provider portal expected to drive longer-term clinical and commercial benefits. Headwinds include a materially higher MLR (85.5% in Q2 vs 71% prior year), a steep decline in Patient Services gross profit (~57% YoY decline), timing delays that push some launches into Q4 and potential variability in pharmacy margin gains. Overall, the positive top-line, profitability improvement, cash flow progress and balance sheet actions outweigh the near-term operational and margin challenges while scaling capitated lives.View all STLN earnings summariesSTLN Stock 12 Month Forecast
Average Price Target
$9.25
▲(41.01% Upside)
Technical Analysis
Ownership Overview
21.39% Insiders
7.06% Mutual Funds
12.56% Other Institutional Investors
49.86% Public Companies and
Individual Investors